No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BGNE BeiGene
- 167.920
- +0.530+0.32%
Close May 22 16:00 ET
- 167.930
- +0.010+0.01%
Post 17:27 ET
17.56BMarket Cap-22279P/E (TTM)
171.830High166.865Low102.68KVolume169.260Open167.390Pre Close17.30MTurnover0.17%Turnover RatioLossP/E (Static)104.58MShares241.50052wk High5.23P/B10.03BFloat Cap126.96852wk Low--Dividend TTM59.74MShs Float426.560Historical High--Div YieldTTM2.97%Amplitude22.510Historical Low168.458Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
An Intrinsic Calculation For BeiGene, Ltd. (NASDAQ:BGNE) Suggests It's 47% Undervalued
Key Insights The projected fair value for BeiGene is US$317 based on 2 Stage Free Cash Flow to Equity Current share price of US$167 suggests BeiGene is potentially 47% undervalued Analyst price t
Glenmark Pharma Arm to Market Two Beigene Cancer Drugs in India
Glenmark Specialty, a subsidiary of Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296), will market Beigene's (SHA: 688235, HKG:6160) oncology medicines, Tislelizumab and Zanubrutinib, in India, acco
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why
BeiGene, Ltd. BGNE is a next-gen oncology company focusing on discovering and developing innovative and affordable treatments for cancer patients worldwide.
Clinical research tool book “Everything is Visible” officially published and sold
BEIJING, May 20, 2024/PRNewswire/ -- BeiGene (NASDAQ: BGNE; Hong Kong Stock Exchange: 06160; Shanghai Stock Exchange: 688235), a global oncology treatment innovation company, today announced that “Everything Visible: Ten Scenarios for Visualization Applications in Clinical Research and Development” (hereinafter referred to as “Everything Visible”), which it co-organized with the Drug Information Association (DIA) China Digital Health Community (DHC)), has officially launched. “Everything is Visible” book cover “Everything Visible” is a systematic introduction to how data visualization can be applied to clinical medical research
[Broker Focus] BOC International's first purchase rating for 5 biotech companies indicates that it is firmly optimistic about the sector's potential for heavy snow
Jinwu Financial News | BOC International released an in-depth report on the biotechnology industry. In 2024, the State Council government work report first proposed speeding up the development of the innovative pharmaceutical industry, building new types of productivity such as biomantry, and encouraging entrepreneurship and equity investment. The bank believes that it will continue to introduce supporting policies in the future to promote the development momentum of pharmaceutical innovation. The bank believes that the sector has opportunities for valuation repair within 2024, mainly considering: 1) there has been a large degree of disconnection in the past year, and the bank is optimistic about the chances of Hong Kong stocks recovering compared to US stocks; 2) important overseas events such as overseas licensing/mergers and acquisitions transactions are expected to continue to be implemented in 2024.
Top Gap Ups and Downs on Thursday: WMT, TM, MUFG and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Comments
» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
6
Last week’s PDUFAs:
$BeiGene(BGNE.US$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$Bristol-Myers Squibb(BMY.US$ : Approved 3/8 🎉
⇒ Opdivo ® + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$Vanda Pharmaceuticals(VNDA.US$ : CRL 3/4 🙁
⇒ HETLIOZ®
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia(EYEN.US$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...
$BeiGene(BGNE.US$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$Bristol-Myers Squibb(BMY.US$ : Approved 3/8 🎉
⇒ Opdivo ® + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$Vanda Pharmaceuticals(VNDA.US$ : CRL 3/4 🙁
⇒ HETLIOZ®
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia(EYEN.US$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...
20
2
The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
$Eyenovia(EYEN.US$ $Vanda Pharmaceuticals(VNDA.US$ $Mirum Pharmaceuticals(MIRM.US$ $Madrigal Pharmaceuticals(MDGL.US$ $Geron(GERN.US$ $Bristol-Myers Squibb(BMY.US$ $2seventy bio(TSVT.US$ $Legend Biotech(LEGN.US$ $OptiNose(OPTN.US$ $Orchard Therapeutics(ORTX.US$ $Merck & Co(MRK.US$ $Akebia Therapeutics(AKBA.US$ $AstraZeneca(AZN.US$ $Liquidia(LQDA.US$ $Esperion Therapeutics(ESPR.US$ $Regeneron Pharmaceuticals(REGN.US$ $BeiGene(BGNE.US$
$Eyenovia(EYEN.US$ $Vanda Pharmaceuticals(VNDA.US$ $Mirum Pharmaceuticals(MIRM.US$ $Madrigal Pharmaceuticals(MDGL.US$ $Geron(GERN.US$ $Bristol-Myers Squibb(BMY.US$ $2seventy bio(TSVT.US$ $Legend Biotech(LEGN.US$ $OptiNose(OPTN.US$ $Orchard Therapeutics(ORTX.US$ $Merck & Co(MRK.US$ $Akebia Therapeutics(AKBA.US$ $AstraZeneca(AZN.US$ $Liquidia(LQDA.US$ $Esperion Therapeutics(ESPR.US$ $Regeneron Pharmaceuticals(REGN.US$ $BeiGene(BGNE.US$
21
$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
6
The research is done by the respective broker and I do not endorse any of them. Just sharing here for information and reading pleasure.
alphaedgeinvest...
$BEIGENE(06160.HK$ $BeiGene(BGNE.US$
alphaedgeinvest...
$BEIGENE(06160.HK$ $BeiGene(BGNE.US$
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg